Audio

Samuel F. Hunter, MD, PhD

Publish date: June 4, 2015

An open-label study indicates that patients with multiple sclerosis may benefit from switching to alemtuzumab.

 

Recommended Reading

Promoting MS Medication Adherence Through Telehealth
MDedge Neurology
Variation in Brain Iron Levels in MS and CIS
MDedge Neurology
Does Education Status Impact MS Risk?
MDedge Neurology
Factors Linking Optic Neuritis to MS Risk
MDedge Neurology
When Patients Don’t Respond to Interferon-β
MDedge Neurology
Life Expectancy and Multiple Sclerosis
MDedge Neurology
Switching From Natalizumab to Dimethyl Fumarate: Real-World Experience
MDedge Neurology
Alemtuzumab May Suppress Disease Activity for Four Years
MDedge Neurology
Daclizumab HYP May Improve Ambulation and Cognition, Compared With Interferon β-1a
MDedge Neurology
Expert: Don’t discourage pregnancy in MS patients; manage it
MDedge Neurology

Related Articles